Monday, June 25, 2018

To experience diversification in the field of gastroenterology , ME Conferences is organizing 17th International Conference on Gastroenterology and Hepatology to be held in Dubai, UAE on September 03-04, 2018. The conference program centers on “Knowing the unknown and finer facts of Gastroenterology”. Gastroenterology and Hepatology Conference 2018 is tied in with giving a bright and educated field for the individuals in the field of Gastroenterology. We attempt to provide a perfect stage to share data and experiences and empower people to total fruitful considers and endeavors to fight against the worldwide risk. We have inquired around inclination from different parts of the world coming to share their most recent research works in the field of gastroenterology.

World Gastroenterology 2018 is a driving stage for a focused plan of the current research in the field of gastroenterology which incorporates, visitor addresses, keynotes, symposiums, workshops, presentations, board talks and poster sessions. We welcome Gastroenterologists, Hepatologists, Common Doctors, Microbiologists, Oncologists, Specialists, Teachers, Analysts, Understudies, Industrial Pharmaceuticals and Business delegates to connect us at Dubai in September 2018 for the 2-day power stuffed Gastroenterology Meet.

Conference Link:-

The Importance of stem cell conference has given us the Possibility to bring the assembling in Prague, Czech Republic. Since its commencement in 2012 Stem cell series has witnessed around 890 researchers of great abilities and Exceptional research presentations from around the world. Attention of stem cells and its application widely prevalent among the Common Population. Stem cells are applicable to understanding the cancer the global stem cells market is segmented according to product type, sources, application, end users and geography and helpful to welfare of mankind. Stem cell medical aid is most promising treatment for diseases like Parkinson’s diseases, Alzheimer's disease, illness} connected disease like leukemia, Parkinson’s, Myelodysplastic Syndromes, Lymphomas, and alternative Disorders.

For discounts and benefits contact manager:

LSW LifeScienceWorld is organizing 4th Edition of Roundtable between Dr. R K Vats, Additional Secretary, Ministry of Health & Family Welfare and some key industry personnel to have a dialogue on regulatory issues concerning drugs and medical devices.

This meeting will be held on April 5, 2018, in Mumbai at the Orchid Hotel.

The Session on Medical Devices will attended by Representatives from MTaI, Medical Technology Association of India, and leading key personnel from major Device companies.

On the Drugs and clinical trial front, Heads of Regulatory Affairs, Medical Directors and some CEOs of major pharma companies will be taking part besides OPPI submitting subjects or core issues.

The objective of this Roundtable is to express and discuss the issues that the Medical Device and pharma industry is facing.

Society for Regenerative Medicine &Tissue Engineering ( SRMTE)
In association with
Ahmedabad University

STEM 2018
14th Annual Conference, 31st January 2018

Venue: Auditorium, GICT Building, Ahmedabad University, University Road, Navrangpura,
Ahmedabad – 380009.

Program Schedule

8:30 – 9:00
9:00 – 9:45
Inaugural Session:
Welcome & Inauguration by Prof. Pankaj Chandra, Vice Chancellor, Ahmedabad University and felicitation for lifetime achievement award
9:45 – 10:00
Vote of Thanks:
Dr. Jyothsna Rao, Secretary, SRMTE
10:00 – 10:15
Habibullah Memorial: 
Oration and Habibullah award
10:15 – 11:00 
Habibullah Memorial lecture by Dr. Aleem A Khan, CLRD, Hyderabad
Tea Break: 11:00 to11:30
11:30 – 12.00 
Dr. Deepa Bhartiya, NIRRH, Mumbai.
12:00 – 12:30 
Dr. Ramesh Bhonde, DYPU, Pune.
12:30 – 1:00 
Dr. Uma Kandalam, Nova University Florida
Lunch Break 1:00 to 2.00
2:00 – 2:30 
Dr. Gopal Pande, SORM, Bangalore
2:30 – 3:00 
Dr. Md.Aejaz Habeeb,
Deccan College of Medical Sciences, Hyderabad.
3:00 – 3:30 
Dr. Gururaj Rao, International Stemcell Services Ltd, Bangalore.

Valedictory and concluding remarks
Tea Break: 4.00 onwards




15th March 2018, Kohinoor Continental Hotel, Mumbai, India

“Understanding recent regulatory developments to explore innovative strategies”

Virtue Insight takes great pleasure to announce the new Pharma Regulatory 2018 conference to be held on 15th March 2018, Kohinoor Continental Hotel, Mumbai, India.

This event is focusing on the clarification and interpretation to the most critical regulatory guidelines faced by the Indian Pharma companies. This unique event will bring key stakeholders gather with the aim of promoting and undertaking to continue work towards a more efficient pharma regulatory system. In the spirit of constructive cooperation, this event brings together representatives from the industry and regulators as well as healthcare professionals. The summit features government and regulatory authorities and expert insights to help you tackle and overcome these regulatory challenges, and to improve the drug and device approval processes for pharmaceutical, biopharmaceutical and medical device companies.


  • RAJENDRA SANGHAVI, Consulting Clinician & Chairman – Medical, Committee, Indian Drug Manufacturers’ Association (IDMA)
  • DEBOLINA PARTAP, Vice President Legal & GC, Wockhardt
  • RAHUL GUPTA, Vice President, Regulatory Affairs, USV
  • PRASHANT DESAI, Director – Regulatory Affairs & Business Quality, Johnson & Johnson
  • YASMIN SHENOY, Director-Regulatory Affairs, Sanofi-Aventis
  • SRIRUPA DAS, Associate Director – Medical Affairs, Abbott
  • NAVEEN KUMAR NAGARAJA, Assistant Director Regulatory Affairs, Takeda
  • SHANTANU MUKHERJEE, Legal Head, Asia Pacific and Japan, Lupin
  • KEDAR SUVARNAPATHAKI, Head – Regulatory Affairs & IP, Boehringer Ingelheim
  • SANJAY KUMAR, Head of Legal Ethics & Compliance, GSK Consumer Healthcare R&D India
  • AMITA BHAVE, Head Regulatory Affairs GDD India, Novartis
  • NARESH TONDARE, Head – India and Nepal Regulatory Affairs, Glenmark Pharmaceuticals
  • SONIKA SHAH, Regulatory Affairs Head, Amgen
  • QAYUM MUKADDAM, Independent Consultant, (Former Head- Medical & Regulatory Affairs -Galderma India)
  • RITU JOHARI, Head-Scientific Affairs, Quality & Regulatory, Abbott Diabetes Care
  • ALAP GANDHI, Head, Medical Affairs, GSK
  • RANJIT BARSHIKAR, QbD / CGMP Consulting, Editorial Member of Journal of Generic Medicine-England
  • PRATIK SHAH, Head- Clinical, Medical & Regulatory Affairs,, PV and QA Astellas Pharma


Specifically designed for pharma, biotech, CRO’s, Government and Regulators, Hospitals/Trial Sites, Technology & Solution Providers and med device professionals responsible for

Regulatory AffairsRegulatory Writing/Medical Writing/Publishing/Information/Submissions, Document and eRecords Management, Business Operations/Processing, Labelling, Clinical Trials Management/Data, Clinical Data, Outsourcing/Clinical Outsourcing/Vendor Management, Product Development, Quality Assurance/Quality Control




Email – or Tel – +91 44 64998743


  • Early Bird Discounted Price (Until 28th January 2018 ) – 1 Delegate Pass – (INR 6,000 + GST (18%) per delegate)
  • Standard Price (From 29th January 2018)  1 or 2 Delegates – (INR 7,000 + GST (18%) per delegate)
  • Group Discounts –3 or 4 Delegates – (INR 6,500 + GST (18%) per delegate)
  • Group Discounts –5 and above Delegates – (INR 6,000 + GST (18%) per delegate)
  • Spot Registration on the day of the Conference –1 Day Conference – (INR 8,000 + GST (18%) per delegate)
  • Conference Sponsor, Exhibition Stall and a paid Speaker Slot are also available.

In order to register you can simply e-mail your invoice details in the below mentioned format; E-mail-

  • Name:
  • GST Number (If Applicable):
  • Company Name & Address:
  • Job Position:
  • Contact Number:

We would be delighted to have you present at this conference which provides insights on the US, Europe and ROW region which presents the major revenue of the top Indian pharmaceutical companies and explore the regulatory developments and innovative strategies.

About ACTIS 2018—Outsourcing,Innovation and Supply

Over the years, Asia has increasingly become the hotbed and destination for the clinical research. From one side, increasingly global pharmaceutical companies have recognized the importance and advantages to integrate Asia into the global early and late phase clinical development but also meanwhile the Asian clinical research markets are further driven and facilitated by the rapidly transforming Asian Local R&D Innovation.

ACTIS2018 are going to be focused on the biggest challenges in the industry currently, including, but not limited to supply requirements and regulation, quality assurance and working with the correct CROs.

A part of our highly successful Clinical Trials series, the event, which attracts over 250 attendees, will build upon ACTIS 2018 and examine partnerships and outsourcing strategies; vendor management, sourcing and selection on both regional and global levels ;key regulatory changes and the effects these have had on Asian market access; best practice techniques in clinical operations; Data Collection, Quality,Safety and Risk Management; and so by visiting you will learn multiple techniques for better vendor sourcing, managing relationships, supply efficiency, trial operations management as well as logistical hurdles such as ‘packaging and labelling’, ‘temperature maintenance and cold chain’, ‘shipping, distribution and logistics’, – all of which will improve the success of your trials and the commercial objectives of your company

With over 40 speakers and estimation to bring over 250 clinical professionals, the key congress topics will cover:

—  Asian Regulation , Development and outsourcing Strategies

—  Asian Clinical Operation and Project Management

—  Drug Safety, Clinical Data Collection and Management

—  Developing the Flexible, Strategic and Innovative Partnership

—  Novel Theories, Clinical Innovation and Quality Assurance

—  Clinical Supply Efficiency, Temperature Maintenance and Cold Chain

—  Packaging and Labelling, Shipping, Distribution and Logistics

On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests and the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and guided networking sessions for all professionals and management who are working for the drug development programs in Asia

Event Name: The 3rd Annual Asia Clinical Trials Innovation Conference 2018

Date:  April 25th to 26th,2018

Venue: Wyndham Bund East Shanghai,China

Contact Person: Marketing Department

Direct Line: 86 21 31602153



Event Name: Pharma/Biotech Project Portfolio Management Masterclass

Event Date: 8 – 10 May 2018

Event Location: Singapore

Contact Email:

Event Website:



The 3-day, practical Biotech/Pharma Project Portfolio Management Masterclass Seminar is specially developed for Heads, Managers and Senior Executives of Biotechnology and Pharmaceutical Companies in charge of strategic planning & development, strategic marketing and business development, new product development, project and/or portfolio management and R&D who are looking to get a more coherent, efficient and comprehensive view of the project portfolio management process and strategy, in order to gain market success.

This Masterclass Seminar is your roadmap to maximizing portfolio value in accordance with management’s strategic and financial goals. Designed to improve companies’ abilities to progress compounds from the pre-clinical stage to commercial brand management, it showcases benchmarks and best practices for teams managing investments across the entire value chain – pre-clinical and clinical projects as well as marketed brand products.


>>> Wish to find out more? Visit the Official Website or Email directly now!

8th  November’17, Mumbai: With the Indian Pharmaceuticals market growing ever larger, The Economic Times saw the need to cultivate a platform for researchers, pharmaceuticals industries, healthcare professionals and various stakeholders to discuss the latest advances in the space. The Economic Times Pharma & Life Sciences Congress 2017, held today at The Taj Vivanta, Mumbai, saw prominent industry experts deliberate on the ‘Future of Pharma & Life sciences.’

The event convened with opening remarks from Dr. Maruthi Viswanathan, Chief Executive Officer, Rx Prism and later a keynote address delivered by Mr. Ranjit Shahni, Vice Chairman & Managing Director, Novartis. In the keynote address, Mr. Shahani highlighted the key trends, opportunities, challenges that the Indian industry faces, stating, “Demographic trends like increase in population, average life expectancy are putting the healthcare system under pressure.”

Setting the tone for the day, Mr. Deepak Lamba, President – Times Strategic Solutions, said, “The Indian Pharma industry is on the threshold of becoming a major global market by 2020. We at ET believe no global pharmaceutical company can afford to ignore India and its growth. We thus wanted to provide a platform to sustain this growth and bring more positive changes through a talented pool of Pharma experts.”

Dilip G Shah, Secretary General, Indian Pharmaceutical Alliance, expanded further, saying, “The future would be less and less predictable and the disruption would come at a faster rate that we have witnessed and this disruption would come from completely unknown parties, like digital or medical science and my discussion with the other industry shows that we are not prepared for future.” To battle these disruptions, Annaswamy Vaidheesh, Vice President, South Asia & Managing Director, GlaxoSmithKline Pharmaceutical, suggested setting up think tanks within the country.

In the session titled Moving Beyond Generics-Innovation in Pharma-the next up, visionaries , Daara Patel, secretary General, IDMA; Jawed Zia, Country President, Novartis and Kanchana TK, Director General OPPI expounded on the manner in which we should look into working with the government from a policy perspective to actually innovate in Pharma. Mr. Patel added, “Most of the patients are not getting medicines due to poor infrastructure. India has affordability but as far as accessibility is concerned it is far behind than any other country in the world.”

The discussion also highlighted that patent protection is a big challenge in pharma innovations. Speakers suggested that the government should free the Pharma industry from the shackles of price control, there is a lot of competition and the industry is mature enough. Only when there is a drastic difference in the price points should the government intervene. It ended on a positive note, with the statement,‘The value of innovation should be seen as an investment not only for health but also for economy.’

Moving forward in a dialogue between Abhishek Lagvankar, Marketing, Medical Nutrition, Danone; Alap Gandhi, Head Medical Affairs, GlaxoSmithKline Pharmaceuticals; Rinkesh Shah, Digital marketing Strategist, Cipla on Pharma Marketing going digital, it was highlighted that digital marketing in Pharma has low awareness as compared to other industries and 70% of today’s population turns to the internet for medical information. They also said most companies develop apps. However, studies have found that 75% of people don’t use the app after 3 months. Hence what will help in moving forward in digital marketing sphere is to have real time patient data and not just attempt to roll out quarterly marketing initiatives. It ended with an insight that Pharma Industries are way behind in applying digital strategy and that it should pick up.

The day concluded with an enlightening discussion between Mr. Shantanu Mukherjee, Legal Head, Asia Pacific and Japan, Lupin and Sudesh Shetty, Partner and Head, Forensics, Life Sciences, KPMG on manufacturing in India, compliance in manufacturing, making it globally compliant and the road ahead. Mr. Sudesh Shetty ended the session with a remark, “The cost of compliance goes exponentially up when it’s reactive.”

About ET Edge:

Times Strategic Solutions Ltd., functional under the brand name ET Edge, is an Economic Times initiative founded to empower multiple industries and segments by sharing critical business knowledge through focused exhibitions and strategic conferences and summits. Encompassing business vistas, ET Edge strives to bring together visionaries and key leaders on its knowledge platforms to create a social and business environment conducive to the positive changes required by the industry. The main aim of this initiative is to channel global business intelligence through exhibitions, summits and conferences in overarching lectures, hands-on workshops, panels, roundtables, case studies and more.

The Ministry of Health & Family Welfare has recently announced the launch of daily regimen for TB patients
across the country under The Revised National TB Control Programme (RNTCP). The Health Ministry has been
providing the thrice weekly regimen for the treatment of tuberculosis (TB), however it has now decided to
change the treatment strategy for TB patients from thrice weekly to daily drug regimen using fixed dose
combinations (FDC) for treatment. This change will bring transformation in the approach and the intensity to
deal with this disease which accounts for about 4.2 lakh deaths every year.

The daily FDC anti-TB drugs will be made available to private pharmacy or at private practitioners to dispense to TB patients who seek care in private sector, depending upon the convenience of patient and practitioner free of cost. The Health Ministry will take this forward with all major hospitals, IMA, IAP and other professional
medical associations to expand the access to daily FDC to all TB patients.

The salient features of this treatment strategy are use of Ethambutol in continuation phase for all patients, drugs to be given daily (as against only 3 times weekly previously), fixed dose combination (FDC) tablets to be used which will reduce pill burden (as against separate 7 tablets previously), for children, child friendly formulations as dispersible tablets and use of Information Technology (IT) enabled treatment adherence support system.

Current WHO Global TB Report, 2017 has reported that incidence of TB has reduced from 28.2 lakh to 27 lakh and mortality by 60 thousand over the last one year, which is a testimony of anti TB drive by Government of India.